Entrada

Entrada Therapeutics Reports Third Quarter 2023 Financial Results

Retrieved on: 
星期二, 十一月 7, 2023
FDA, United Kingdom, Clinical trial, Vertex, Food, Dystrophin, Toxicology, Neurodegenerative disease, G&A, MNGIE, Research and development, CTA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Research, Volunteering, R, Enzyme replacement therapy, Pharmacokinetics, Male, Growth, Thymidine, Entrada, Duchenne muscular dystrophy, General Administration of Sport of China, Safety, DMD, Therapy, Patient, Administration, Encephalopathy, Pharmaceutical industry, IND, Duchenne

BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today reported financial results for the third quarter ending September 30, 2023, and highlighted recent business updates.

Key Points: 
  • In July 2023, Entrada entered into a license agreement to advance the development of ENTR-501 with Pierrepont Therapeutics, Inc., a mitochondrial disease-focused company.
  • Research & Development (R&D) Expenses: R&D expenses were $22.2 million for the third quarter of 2023, compared to $19.0 million for the same period in 2022.
  • General & Administrative (G&A) Expenses: G&A expenses were $7.5 million for the third quarter of 2023, compared to $7.0 million for the same period in 2022.
  • Net Income (Loss): Net income was $35.5 million for the third quarter of 2023, compared to a net loss of $(25.1) million for the same period in 2022.

Entrada Therapeutics to Present at Upcoming Investor Conferences

Retrieved on: 
星期四, 十月 12, 2023
Beckman Center for Molecular and Genetic Medicine, DMD, Trajectory, Medication, Entrada, Therapy, Evercore, Conference, Patient, Pharmaceutical industry

BOSTON, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced it will participate in the following two investor conferences:

Key Points: 
  • BOSTON, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced it will participate in the following two investor conferences:
    Nathan Dowden, Chief Operating Officer, will participate on the Changing the Trajectory of Neuromuscular Diseases: DMD and Beyond virtual panel on Monday, October 16, 2023 at 11:00 a.m. Eastern Time.
  • Dipal Doshi, President and Chief Executive Officer, will participate in an in-person fireside chat on Wednesday, November 29, 2023 at 3:50 p.m. Eastern Time in Miami, FL.
  • A live webcast of the fireside chat at the Evercore ISI 6th Annual HealthCONx Conference and a replay of the panel at William Blair's Innovator Series: Genetic Medicines will be available on the Investor Relations section of the Company’s website at www.entradatx.com .
  • The replay of the fireside chat will be available on the Entrada website for 90 days and the replay of the panel will be available for 7 days following the events.

Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

Retrieved on: 
星期四, 九月 21, 2023
Volunteering, Male, Duchenne muscular dystrophy, Neurodegenerative disease, Pharmacokinetics, Duchenne, Entrada, Patient, United Kingdom, Growth, Therapy, Safety, Pharmaceutical industry

BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced that the first participant has been dosed in its Phase 1 clinical trial evaluating ENTR-601-44 for the potential treatment of individuals with Duchenne muscular dystrophy who are exon 44 skipping amenable.

Key Points: 
  • BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced that the first participant has been dosed in its Phase 1 clinical trial evaluating ENTR-601-44 for the potential treatment of individuals with Duchenne muscular dystrophy who are exon 44 skipping amenable.
  • “The initiation of our Phase 1 trial for ENTR-601-44 is an important step forward in addressing this relentlessly progressive neurodegenerative disease,” said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics.
  • “Today’s announcement marks Entrada’s transition into a clinical company.
  • The trial will also evaluate pharmacokinetics and target engagement, as measured by exon skipping in the skeletal muscle.

Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community

Retrieved on: 
星期四, 九月 7, 2023
Therapy, Education, Street of Dreams (Grant Green album), Social support, Biological and Chemical Defence Review Committee, Private practice, Equity, Entrada, Assistant, Organization, Central Commission for Discipline Inspection, Pediatric Neurology, Representation, Patient, Division, PPMD, Akari, Neurology, Hospital, Rare, DREAMS, Disease, Pharmaceutical industry, Nursing, Management, Pediatrics, Duchenne, MD

BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEVÔ) therapeutics as a new class of medicines, today announced recipients of its inaugural Entrada Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program. Entrada DREAMS grant recipients – The Akari Foundation, Neurology and Neuromuscular Care Center and Parent Project Muscular Dystrophy (PPMD) – will each be awarded $25,000 to support initiatives that aim to better identify, understand and reach those within the Duchenne community who are currently underrepresented or underserved.

Key Points: 
  • Funding provided by Entrada will support the clinic in hiring its first mental health professional.
  • This individual will help to address gaps in socioeconomic health needs by providing emotional and social support to people and families living with Duchenne.
  • Parent Project Muscular Dystrophy (PPMD) Foundation is a patient advocacy organization fighting to end Duchenne by helping those living with the condition to lead longer, stronger lives.
  • On behalf of the DREAMS Review Committee, we congratulate these three vital organizations and we look forward to seeing the lasting impact that their work will continue to have on the Duchenne community.”

Clearwater CFO Baxter Lee Named to Tennessee HIMSS Board

Retrieved on: 
星期二, 九月 12, 2023
Ardent Health Services, NextGen Healthcare, Jude the Apostle, Child, Entrada, HIMSS, Health care, Acquisition, St. Jude Children's Research Hospital, St. Jude's, CFO, Growth, CIO, Hospital, SVP, Management, Nursing, Change Healthcare

NASHVILLE, Tenn., Sept. 12, 2023 /PRNewswire-PRWeb/ -- Clearwater, the largest pure-play provider of cybersecurity and compliance solutions for healthcare organizations, is proud to announce that its Chief Financial Officer (CFO) Baxter Lee has been named to the Tennessee HIMSS Board of Directors for a one-year term beginning January 1, 2024.

Key Points: 
  • NASHVILLE, Tenn., Sept. 12, 2023 /PRNewswire-PRWeb/ -- Clearwater, the largest pure-play provider of cybersecurity and compliance solutions for healthcare organizations, is proud to announce that its Chief Financial Officer (CFO) Baxter Lee has been named to the Tennessee HIMSS Board of Directors for a one-year term beginning January 1, 2024.
  • Clearwater, the largest pure-play provider of cybersecurity and compliance solutions for healthcare organizations, is proud to announce that its Chief Financial Officer (CFO) Baxter Lee has been named to the Tennessee HIMSS Board of Directors for a one-year term beginning January 1, 2024.
  • "I am honored and excited to serve the healthcare community as an incoming Tennessee HIMSS board member," Lee said.
  • "Baxter has been a fierce advocate for health tech in Nashville and across the state of Tennessee throughout his career," said Clearwater CEO Steve Cagle.

Entrada Therapeutics to Present at Upcoming Investor Conferences

Retrieved on: 
星期二, 八月 29, 2023
Therapy, Patient, Entrada, Pharmaceutical industry

BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the Company will participate in two investor conferences in September.

Key Points: 
  • BOSTON, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the Company will participate in two investor conferences in September.
  • Dipal Doshi, President and Chief Executive Officer, will join an in person fireside chat on Thursday, September 7, 2023 at 9:30 a.m.
  • Live webcasts will be available on the Investor Relations section of the Company’s website at www.entradatx.com .
  • Replays will be available on the Entrada website for 90 days following the events.

Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

Retrieved on: 
星期四, 八月 10, 2023
Gilead Sciences, Duchenne muscular dystrophy, Therapy, Senior, EEV, Clinical trial, Cancer, Genentech, Entrada, CAR, Patient, Ophthalmology, Hematology, Growth, Neurology, Pharmaceutical industry

BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the appointment of Gina Chapman to its Board of Directors, effective September 1, 2023.

Key Points: 
  • BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced the appointment of Gina Chapman to its Board of Directors, effective September 1, 2023.
  • Ms. Chapman currently serves as President and Chief Executive Officer of CARGO Therapeutics.
  • “Gina is a seasoned leader with more than thirty years of experience driving the commercial and operational growth of numerous biopharmaceutical companies,” said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics.
  • “The broad potential of Entrada’s EEV platform to engage intracellular disease-causing targets provides the opportunity to address diseases where treatment options are unavailable or limited.

Entrada Therapeutics Reports Second Quarter 2023 Financial Results

Retrieved on: 
星期二, 八月 8, 2023
Ethics committee, Research and development, Pharmacokinetics, G&A, Research, Duchenne, Entrada, REC, MHRA, Clinical trial, Patient, Administration, United Kingdom, Medicines and Healthcare products Regulatory Agency, R, FDA, Wells Fargo, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, General Administration of Press and Publication, Therapy, Safety, Conference, Food, Cryptocurrency, Pharmaceutical industry, Video game

BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today reported financial results for the second quarter ending June 30, 2023, and highlighted recent business updates.

Key Points: 
  • – $377 million in cash, cash equivalents and marketable securities as of June 30, 2023 –
    BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today reported financial results for the second quarter ending June 30, 2023, and highlighted recent business updates.
  • Research & Development (R&D) Expenses: R&D expenses were $26.3 million for the second quarter of 2023, compared to $16.2 million for the same period in 2022.
  • General & Administrative (G&A) Expenses: G&A expenses were $8.2 million for the second quarter of 2023, compared to $7.3 million for the same period in 2022.
  • Net Loss: Net loss was $25.9 million for the second quarter of 2023, compared to a net loss of $23.2 million for the same period in 2022.

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

Retrieved on: 
星期二, 八月 1, 2023
Ethics committee, Duchenne muscular dystrophy, Therapy, Pharmacokinetics, Duchenne, Entrada, REC, MHRA, Clinical trial, Patient, Medicines and Healthcare products Regulatory Agency, Phase 1, Safety, Pharmaceutical industry

BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced that it has received authorization from the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee (REC) for its CTIMP (Clinical Trial of an Investigational Medicinal Product) for a Phase 1 clinical trial in healthy volunteers for ENTR-601-44. ENTR-601-44 is Entrada’s lead product candidate within its Duchenne franchise and is being developed for the potential treatment of individuals with Duchenne who are exon 44 skipping amenable.

Key Points: 
  • ENTR-601-44 is Entrada’s lead product candidate within its Duchenne franchise and is being developed for the potential treatment of individuals with Duchenne who are exon 44 skipping amenable.
  • “We are looking forward to this important next step in advancing ENTR-601-44 for the potential treatment of people with exon 44 skipping amenable Duchenne muscular dystrophy, where there exists a profound unmet medical need,” said Dipal Doshi, President and Chief Executive Officer of Entrada Therapeutics.
  • The trial will also evaluate tolerability, pharmacokinetics and target engagement as measured by exon skipping in the skeletal muscle.
  • The first participant is expected to be dosed in September of this year with data anticipated in the second half of 2024.

Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference

Retrieved on: 
星期二, 六月 6, 2023
Goldman Sachs, Entrada, Therapy, Goldman, Patient, Conference, Pharmaceutical industry, Online shopping

BOSTON, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA.

Key Points: 
  • BOSTON, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of medicines, today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA.
  • The fireside chat will be held on Wednesday, June 14, 2023 at 10:40 a.m. Pacific Time/1:40 p.m. Eastern Time.
  • A live webcast will be available on the Investor Relations section of the Company’s website at www.entradatx.com .
  • A replay will be available on the Entrada website for 90 days following the event.